The First Triple Agonist for Antiobesity: Retatrutide.
Retatrutide shows promise as a weight loss medication, particularly in higher doses, but further details on efficacy and safety are needed for clinical application.
Where it sits
this study against the rest of the retatrutide (ly3437943) corpusSummary and findings
Retatrutide, a triple agonist, was evaluated for its effects on weight loss in individuals with obesity and/or type 2 diabetes. Phase 1 and 2 clinical trials indicated safety and tolerability, with a mean half-life of approximately 6 days supporting once-weekly dosing. Greater weight loss was observed with retatrutide compared to placebo, particularly at higher doses.
Abstract
The prevalence of individuals with overweight and obesity has increased by 18% since 1990 and it is projected that by 2030, nearly 50% of US adults will have obesity. Lifestyle modifications, such as diet and exercise, typically lead to approximately 3-5% weight loss, whereas 5-15% weight loss is necessary to significantly impact obesity-associated comorbidities and improve overall health outcomes. In addition to lifestyle modifications, pharmacotherapy has been utilized as an adjunctive treatment to increase weight loss and improve health outcomes. The Food and Drug Administration has currently approved 6 drugs to treat overweight and obesity, with the recently approved drugs surging in popularity after demonstrating superior weight loss outcomes. Additionally, a number of agents are in the pipeline, offering promise of unprecedented degrees of weight loss. One such drug is retatrutide, which is a triple agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor, and glucagon receptor. Phase 1 and 2 clinical trials have demonstrated the safety, tolerability, and pharmacokinetics of retatrutide in patients with obesity and/or type 2 diabetes. The pharmacokinetics of retatrutide were dose proportional and its mean half-life of approximately 6 days supported a once-weekly dosing. The safety profile was similar to GLP-1R agonists and glucose-dependent insulinotropic polypeptide receptor/GLP-1R co-agonists, with gastrointestinal disorders being the most common adverse effects reported. Each trial demonstrated greater weight loss with retatrutide treatment in comparison to placebo, with greatest efficacy at higher doses. Overall, these clinical trials have demonstrated the superior efficacy of retatrutide as a weight loss medication in patients with overweight and obesity.
Background
The study addresses the rising prevalence of obesity, which has increased by 18% since 1990, with projections indicating that nearly 50% of US adults will be affected by 2030. Previous treatments, including lifestyle modifications, typically yield a modest 3-5% weight loss, while a 5-15% reduction is necessary to significantly improve health outcomes. The introduction of retatrutide as a triple agonist targeting multiple receptors offers a potential advancement in pharmacotherapy for obesity.
Methods
The study involved Phase 1 and 2 clinical trials assessing retatrutide in patients with obesity and/or type 2 diabetes. Specifics regarding the population size (n), dosing, duration, and primary versus secondary outcome measures are not detailed in the abstract.
Results
Not reported in abstract.
Interpretation
The findings suggest that retatrutide may provide greater weight loss compared to existing treatments, although the abstract does not specify the magnitude of this effect. Without detailed numeric outcomes, it is difficult to assess the clinical significance of the reported weight loss. Potential confounding factors include the lack of detailed methodology and results, which limits the ability to draw firm conclusions about its efficacy.
Key findings
- mean half-life of approximately 6 days
- greater weight loss with retatrutide treatment in comparison to placebo
- greatest efficacy at higher doses
Limitations
- specific n not reported
- no detailed dosing information provided
- no numeric outcomes reported
- abstract does not specify duration of trials
- no information on funding sources or potential conflicts of interest